The Life Sciences team advised CellCentric on the completion of an oversubscribed $220 million Series D financing. The financing was led by specialist investor Venrock Healthcare Capital Partners, with participation from a strong syndicate of new and existing investors. Proceeds will support the advancement of inobrodib through pivotal clinical development studies, including continued enrollment of the company’s recently initiated Phase 2 DOMMINO-1 study in the UK and US and initiation of the global Phase 3 DOMMINO-2 trial in the second half of 2026. Capital raised will also fund expansion of inobrodib into additional combination and maintenance treatment settings.
CellCentric is a privately held biotechnology company advancing inobrodib, a first-in-class, orally bioavailable p300/CBP inhibitor. Inobrodib is in registration-enabling clinical trials for patients with relapsed/refractory multiple myeloma, with additional indications under consideration. CellCentric is supported by a robust IP portfolio and external validation through clinical collaborations and strategic partnerships. Founded in Cambridge, UK, the company operates as a transatlantic business with offices in Boston.
The Goodwin team was led by Andrew Harrow, Michael Grainger, Hattie Muncey and Claudia Baldelli.
For more information on the deal, please read the press release.